Search

Etrolizumab

[A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal … Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration

XL281

XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers. … Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer.

XL844

XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents. … XL844 is investigated for the use and treatment solid tumors. XL844 is a solid.

NP2

It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain). … NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.

Dansylamide

CGC-11047

CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

TM30339

TM30339 is an analogue of the natural hormone Pancreatic Polypeptide (PP), which is released in connection with meals. … TM30339 thus imitates a natural mechanism, a satiety signal from the gastrointestinal system involved in the regulation of food intake in humans. TM30339 is developed for the treatment of obesity.

TA-CIN

TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.

Cymarin

ACA 125

ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas. … To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported.